Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.66 |
| ▸ | BRAF | P15056 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668547 | 0.80 | MAPK14 (1.00) | MAPK14BRAFMAPK11 | |
| SCHEMBL1012412 | 0.80 | MAPK14 (0.60) | MAPK14BRAFCYP2C19CYP2C9MAPK13 | |
| SCHEMBL13487565 | 0.77 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1080897 | 0.77 | ALDH1A1 (0.56) | MAPK14CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL14177164 | 0.75 | MAPK14 (0.60) | MAPK14CYP2C9MAPK13MAPK12MAPK11 | |
| SCHEMBL14129185 | 0.74 | MAPK14 (0.48) | MAPK14CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL12636203 | 0.74 | MAPK14 (0.48) | MAPK14CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL16150798 | 0.73 | CNR1 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12636211 | 0.72 | MAPK14 (0.47) | MAPK14BRAFCYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL13791346 | 0.69 | MAPK14 (0.79) | MAPK14CYP2C9MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885BRAF 79/4885CYP2C19 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.